Financial Perspectives, Inc Bei Gene, Ltd. Transaction History
Financial Perspectives, Inc
- $264 Billion
- Q1 2024
A detailed history of Financial Perspectives, Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Financial Perspectives, Inc holds 869 shares of BGNE stock, worth $139,848. This represents 0.05% of its overall portfolio holdings.
Number of Shares
869
Previous 869
-0.0%
Holding current value
$139,848
Previous $157 Million
13.29%
% of portfolio
0.05%
Previous 0.06%
Shares
8 transactions
Others Institutions Holding BGNE
# of Institutions
214Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.7 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.14 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$833 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$805 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$600 Million0.46% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $16.7B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...